Calculus Venture Capital Research
Investment Thesis
Calculus Venture Capital is a San Mateo, California deep-tech investment firm launched in May 2025 by Swati Chaturvedi, who coined the term "deep technology" in 2013 and previously built the Propel(x) syndication platform (portfolio raised $1.5B+, with a notable IPO exit in Smoltek). Calculus VC operates under the belief that we are entering a "Deeptech Century" driven by advances in AI, quantum computing, and programmable biology. The firm organizes its thesis around three pillars, published on its site: the Future of Computing and AI (large quantitative models, new compute materials beyond silicon, immersive/neural interfaces), Computational Life Sciences and HealthTech (AI-first therapeutics and discovery platforms, infrastructure for programmable biology, continuous/personalized care), and Advanced Industrial Technologies (AI and automation in industry, land/ocean/space transport and communications, resource efficiency). A distinguishing feature of Calculus VC's approach, relative to earlier-stage deeptech funds, is that it requires scientific proof-of-concept before investing rather than backing pure science projects pre-validation.
Stage Focus
Calculus VC invests at Series A and Series B. This is corroborated by the firm's LinkedIn page and third-party investor guides, both describing the fund as focused on startups that have already cleared scientific proof-of-concept and are ready to scale, rather than pre-seed or seed deeptech bets.
Check Size
No specific check-size range is publicly disclosed. Across all three confirmed investments (SimBioSys, Trailhead Biosystems, CloudNC) Calculus VC wrote checks as part of larger syndicates alongside a lead investor, rather than disclosing a standalone ticket size.
Lead Tendency
Calculus VC follows rather than leads. SimBioSys's round was one of 11+ investors; MAK Capital led Trailhead Biosystems' financing (Calculus joined as a syndicate participant); and Nimble Ventures led CloudNC's $20M Series B extension (Calculus VC, Entrepreneur First, and LM Ventures participated alongside Lockheed Martin's venture arm).
Recent Activity
The fund held its first close in late 2025 and is actively deploying from Calculus Fund I. Three investments are now publicly confirmed: SimBioSys (Calculus VC's first-ever investment, announced December 2025 - a precision-oncology software company behind the FDA-cleared TumorSight Viz breast-cancer surgical-visualization product), Trailhead Biosystems (announced August 2026, a Cleveland Clinic/Case Western spinout building an AI- and robotics-driven cell-differentiation platform for drug discovery and cell therapy, alongside MAK Capital), and CloudNC (announced September 2026, an AI-powered CAM/manufacturing software company, via a $20M Series B extension led by Nimble Ventures). The firm publishes a regular thesis blog ("The Moat Wears a Harness," September 2026; "Situational Awareness Meets Margin Cell," August 2026; "Getting a Feel for Physical AI," July 2026) exploring its Physical AI and industrial-automation thesis. GP Swati Chaturvedi is scheduled to moderate the Physical AI and Robotics panel at the 10th Annual MIT AI Conference on October 17, 2026, and the firm co-hosted an investor/founder dinner with Morgan Stanley Private Wealth Management in Palo Alto in September 2026.
Portfolio Highlights
Confirmed portfolio companies are SimBioSys (simbiosys.com), Trailhead Biosystems (trailbio.com), and CloudNC (cloudnc.com). Given the fund's May 2025 founding, the portfolio is still small and forming; no exits have been disclosed for Calculus Fund I itself. Note that Healx, an AI drug-discovery company GP Swati Chaturvedi backed in 2022 with three drug candidates now in Phase 2 trials, was a Propel(x) syndicate deal predating Calculus VC's founding and is not a Calculus Fund I portfolio company - it is referenced only as evidence of the GP's pre-fund track record in AI-driven biotech.
Team
- Swati Chaturvedi, General Partner - Coined the term "deep technology" in 2013; founded MIT Angels; CEO and co-founder of Propel(x), a deeptech syndication platform whose collective portfolio raised over $1.5B; MBA from MIT Sloan, M.S. from MIT and UC Berkeley, degree from IIT Roorkee, India. Recognized with a World Technology Award (2016) and named an Inspiring Fintech Female (2021) and one of the Bay Area's Most Influential Women (2021).
- Jason May, Technical Due Diligence - Leads technical evaluation of prospective investments.
- Hasmita Kapoor, Marketing & Operations - Oversees the firm's marketing and operational functions.
- Vincent Granville, Advisor - Provides advisory support; also associated with bondingAI.
Decision Process
Calculus VC functions as a solo-GP-led firm: Swati Chaturvedi is the sole General Partner and investment decision-maker, supported by a small team handling technical diligence, marketing/operations, and advisory input rather than co-equal investment partners.
Founder Preferences
Calculus VC favors scientist-founder teams paired with an experienced operating executive - for example, Trailhead Biosystems' scientist-founder Dr. Jan Jensen alongside CEO David Llewellyn. The firm places heavy weight on defensible, hard-to-replicate science combined with a credible path to commercial traction, and requires a working prototype or initial commercial validation before investing rather than backing pre-proof-of-concept science.
Geographic Focus
Primarily the United States, consistent with the firm's San Mateo, California headquarters and Silicon Valley/Bay Area network (Propel(x), MIT Angels), though CloudNC (London-based) shows willingness to invest internationally as part of a syndicate.